Bay Street News, August 6th, 2020

JENA, Germany, Aug. 06, 2020 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by […]

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials —— Enrolled first biliary atresia patients in […]

– Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 –– Continued progress […]

FORT MYERS, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announces the […]

Submitted first regulatory application to the U.K.’s MHRA to initiate a Phase 1 study of NTLA-2001 for the treatment of […]

Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel […]

Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in […]

Financial HighlightsQ2 revenue declined 28.7% or 27.7% in constant currencyQ2 operating earnings of $11.1 million, down 68.2%, or down 50.4% […]

Cronos Israel commenced the sale of PEACE NATURALS™ products to the Israeli medical cannabis marketNatuera completed three additional test exports of […]

SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company […]